Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 105 participants.
Also called NCT03371355
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 105 participants
- Registry
-
NCT03371355
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada
- Registry status
- Completed
Technical summary
Registry record NCT03371355. Randomized; triple masking; primary purpose treatment. Start 2017-12-21 (actual); primary completion 2019-11-21 (actual). Results posted on 2021-02-01.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease
- Condition
- NAFLD
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Hypertriglyceridemia
- Condition
- Fatty Liver, Nonalcoholic
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- ISIS 703802 40 mg
- Intervention (Drug)
- ISIS 703802 80 mg
- Intervention (Drug)
- ISIS 703802 20 mg
- Lead sponsor
- Akcea Therapeutics
- Collaborator
- Ionis Pharmaceuticals, Inc.
Record details
- Record id
cardio:ct-nct03371355- Content hash
121d2504390b2345013fff22b0ba6f4aea6630edeb9821629a7bd0861d7932e9